-
Antiarrhythmic Drugs and KCa2 Channels in AF
2026-09-13
The reference study systematically examined whether established antiarrhythmic drugs modulate human KCa2.2 and KCa2.3 channels, an atrial-enriched target proposed for safer atrial fibrillation therapy. Automated whole-cell patch-clamp data identified inhibition by dofetilide and propafenone, but the large potency gap relative to therapeutic free plasma exposure argues against KCa2 blockade as a major explanation for their clinical actions.
-
Partial BACE Inhibition and Synaptic Transmission
2026-09-12
Satir et al. showed that partial BACE inhibition can reduce amyloid beta secretion without measurably impairing synaptic transmission in cultured rat cortical neurons. The study supports a dose-dependent therapeutic window for Alzheimer’s disease research, while also showing that stronger inhibition was associated with reduced synaptic function.
-
HLTP1 Suppresses JNK in Liver Ischemia-Reperfusion Injury
2026-09-12
This study identifies human liver transplantation peptide 1 (HLTP1) through peptidomic analysis of clinical liver-transplant samples and shows that it reduces hepatic ischemia-reperfusion injury in mice and hepatocyte-like AML12 cells. The findings connect HLTP1 protection to suppression of JNK phosphorylation and apoptosis, while also establishing a translational framework for evaluating DNA fragmentation and cell-death endpoints.
-
Trichostatin A: From HDACs to Tumor Immunity
2026-09-11
Trichostatin A (TSA) is more than a broad HDAC inhibitor: it is a powerful probe for connecting chromatin acetylation with tumor-cell state and immunogenicity. This article translates CBX2–RACK1–HDAC1 biology into practical assay decisions while distinguishing established evidence from testable hypotheses.
-
FH1 Small Molecule for iHep Maturation
2026-09-11
FH1 supports a practical strategy for improving functional readouts in iPS-derived hepatocyte-like cells, with reported gains in albumin secretion, CYP3A4 levels, colony morphology, and AFP reduction. This guide connects FH1 handling with staged differentiation, multiparametric validation, troubleshooting, and carefully bounded applications in liver model and gene-regulation research.
-
Tofacitinib Repairs RA Macrophage Inflammation
2026-09-10
A 2026 study shows that Tofacitinib reverses the inflammatory, metabolic, and mitochondrial abnormalities induced by GM-CSF in rheumatoid arthritis macrophages. Its distinctive effect was linked to reduced GM-CSFRα expression and impaired STAT5 signaling, connecting cytokine control with restoration of macrophage regulatory and mitochondrial states.
-
CUDC-907: Practical Dual PI3K/HDAC Workflow
2026-09-10
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled cell-based studies of PI3K/AKT signaling pathway inhibition, histone deacetylase activity, apoptosis, and cell-cycle progression. It is intended for scientific research workflows only and should not be used for diagnostic, therapeutic, or clinical applications.
-
CUDC-907: Practical PI3K/HDAC Workflow
2026-09-09
CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for controlled studies of PI3K/AKT signaling, histone acetylation, cell-cycle behavior, and apoptosis in cultured cancer models. This guide covers preparation, starting treatment conditions, controls, and assay interpretation; the compound is for scientific research only and should not be used for diagnostic, therapeutic, or clinical applications.
-
PBA-Modified PAD4 Inhibitors Target Tumor NETs
2026-09-09
The reference study developed phenylboronic acid-modified PAD4 inhibitors to combine tumor-biased uptake with suppression of the PAD4–H3cit–NET pathway. Its lead compound reduced tumor growth and lung metastasis in mouse models while reshaping neutrophil and macrophage features, providing a mechanistic framework for studying tumor-directed PAD4 inhibition.
-
Rucaparib (AG-014699) in DNA Repair Workflows
2026-09-08
Rucaparib (AG-014699) supports controlled studies of PARP1 inhibition, DNA damage, and radiation response across prostate cancer and hepatocellular carcinoma models. This guide connects practical dosing, γ-H2AX and p53BP1 assays, spliceosome-linked biomarkers, transporter effects, and troubleshooting for reproducible cancer research.
-
Nurr1+ Neuron Gradients in the Rat Claustrum
2026-09-08
Fang, Wang, and Naumann combine developmental Nurr1 mapping with EdU birth dating to resolve when claustral and lateral cortical neuron populations arise in the rat. Their results reveal sequential neurogenesis and region-specific ventral-to-dorsal and posterior-to-anterior gradients, providing a framework for interpreting claustrum organization beyond static anatomical boundaries.
-
Sphingosine-1-phosphate: Assay Workflow Guide
2026-09-07
Build more reproducible S1P experiments by combining fresh-solution handling, receptor-aware controls, and time-resolved apoptosis or endothelial assays. This guide translates evidence on the S1P/S1PR3 axis into practical workflows for cell survival, vascular biology, and caspase signaling studies.
-
UK-5099: A Causal Map of Metabolic Perturbation
2026-09-05
UK-5099 (PF-1005023) is more than a mitochondrial pyruvate transport inhibitor: it is a useful causal probe for linking fuel entry, cellular energetics, and immune or glucose-related outputs. This article presents an interpretation-first framework grounded in standardized whole-blood stimulation and metabolic phenotyping.
-
Scalable iMSC-EV Manufacturing for Pulmonary Fibrosis
2026-09-05
Gong et al. developed a bioreactor-based platform that converts extended pluripotent stem cells into induced mesenchymal stem cells and produces extracellular vesicles at a scale relevant to translational research. The resulting iMSC-EVs showed primary MSC-EV-like characteristics and therapeutic activity in a bleomycin-induced pulmonary fibrosis model, while addressing donor variability and limited expansion.
-
Hoechst 33342/PI Double Staining Kit Guide
2026-09-04
The Hoechst 33342/PI Double Staining Kit enables Hoechst 33342 propidium iodide staining to compare nuclear morphology with plasma-membrane integrity. The dual-readout fluorescent apoptosis assay supports research classification of viable, apoptotic, and membrane-compromised cells, but it does not independently establish a complete cell-death mechanism.